FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1780 April 26, 2007 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Druker, B. J. PubMed Citation

To the Editor: Druker et al. (Dec. 7 issue)¹ update the data for patients who received imatinib as first-line therapy for chronic myeloid leukemia (CML). However, they do not present most of the data according to the intention-to-treat principle. The survival curves in the article were obtained by censoring data from considerable numbers of patients who did not adhere to the treatment. We infer from Figure 2 of the article that data for 111 of the 553 patients who were assigned to receive imatinib (20%) were censored before month 48 for the analysis of survival without progression, and we infer . . . [Full Text of this Article]

This article has been cited by other articles:

• de Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., Marin, D. (2008). Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis. JCO 26: 3358-3363 [Abstract] [Full Text]